Tom 14, Nr 1 (2020)
Wybrane problemy kliniczne
Opublikowany online: 2020-03-01

dostęp otwarty

Wyświetlenia strony 329
Wyświetlenia/pobrania artykułu 142
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Is there an association between hereditary hemochromatosis and colon cancer in children?

Teresa Stachowicz-Stencel1, Anna Synakiewicz1
Forum Medycyny Rodzinnej 2020;14(1):40-44.


Colon cancer is very rare in children and adolescents, so it remains in an advanced stage at diagnosis. Hereditary hemochromatosis (HH) is an autosomal recessive disease in which iron overload leads to dysfunction of several organs. Elevated body iron stores has association between HFE genotype and risk for some types of cancer. There are HFE gene mutations, including the C282Y and the H63D mutation in the majority of individuals with phenotypic hemochromatosis. The HFE gene mutations may predispose to an increasing risk of colon cancer. Careful clinical and colonoscopic evaluation in patients with these mutations may lead to detect cancer at an earlier stage. We report a case of adenocarcinoma of the colon in 17-year old male with HH and risk of gastrointestinal cancer in patients with hemochromatosis gene mutations.

Artykuł dostępny w formacie PDF

Pokaż PDF (angielski) Pobierz plik PDF


  1. Shaheen NJ, Silverman LM, Keku T, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003; 95(2): 154–159.
  2. Katsarou MS, Papasavva M, Latsi R, et al. Hemochromatosis: Hereditary hemochromatosis and HFE gene. Vitam Horm. 2019; 110: 201–222.
  3. West AR, Oates PS. Mechanisms of heme iron absorption: current questions and controversies. World J Gastroenterol. 2008; 14(26): 4101–4110.
  4. Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA. 2001; 285(17): 2216–2222.
  5. Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology. 2010; 139(2): 393–408, 408.e1.
  6. Brandhagen DJ, Fairbanks VF, Baldus WP, et al. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol. 2000; 95(10): 2910–2914.
  7. Gochee PA, Powell LW, Cullen DJ, et al. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002; 122(3): 646–651.
  8. Olynyk JK, Trinder D, Ramm GA, et al. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008; 48(3): 991–1001.
  9. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009; 100(1): 9–16.
  10. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013; 13(5): 342–355.
  11. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010; 51(4): 1311–1318.
  12. Shaheen NJ, Silverman LM, Keku T, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003; 95(2): 154–159.
  13. Robinson JP, Johnson VL, Rogers PA, et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14(6): 1460–1463.
  14. Bacon BR, Adams PC, Kowdley KV, et al. American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(1): 328–343.
  15. Gurrin LC, Bertalli NA, Dalton GW, et al. HealthIron Study Investigators. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology. 2009; 50(1): 94–101.
  16. Weber ML, Schneider DT, Offenmüller S, et al. Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes. Pediatr Blood Cancer. 2016; 63(4): 611–617.
  17. Angelini C, Crippa S, Uggeri F, et al. Colorectal cancer with neuroendocrine differentiation in a child. Pediatr Surg Int. 2005; 21(10): 839–840.
  18. Goldberg J, Furman WL. Management of colorectal carcinoma in children and young adults. J Pediatr Hematol Oncol. 2012; 34 Suppl 2: S76–S79.
  19. Pox CP, Schmiegiel W. German53-guideline colorectal carcinoma. Dusch Med Wechenschr. 2013(128): 25–45.
  20. Ladd AP, Grosfeld JL. Gastrointestinal tumors in children and adolescents. Semin Pediatr Surg. 2006; 15(1): 37–47.
  21. Beguin Y, Aapro M, Ludwig H, et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. Crit Rev Oncol Hematol. 2014; 89(1): 1–15.
  22. de Almeida SF, Carvalho IF, Cardoso CS, et al. HFE cross-talks with the MHC class I antigen presentation pathway. Blood. 2005; 106(3): 971–977.
  23. Chang VC, Cotterchio M, Khoo E. Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis. BMC Cancer. 2019; 19(1): 543.
  24. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk--a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomarkers Prev. 2014; 23(1): 12–31.
  25. Bastide NM, Pierre FHF, Corpet DE. Heme iron from meat and risk of colorectal cancer: a meta-analysis and a review of the mechanisms involved. Cancer Prev Res (Phila). 2011; 4(2): 177–184.
  26. Chua ACG, Klopcic B, Lawrance IC, et al. Iron: an emerging factor in colorectal carcinogenesis. World J Gastroenterol. 2010; 16(6): 663–672.